Rachel Klemovitch, Assistant Editor04.16.24
Tela Bio. launched the OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix in the US. OviTex is designed for laparoscopic and robotic-assisted inguinal hernia repair.
Available in three configurations, OviTex consists of a three or four-layer anatomically shaped device or a three-layer rectangular device. This provides surgeons with a variety of options to address unique patient, technique, or procedure-related characteristics. Each configuration is designed for trocar compatibility to enhance the use of these products in laparoscopic and robotic procedures.
Building on the existing OviTex portfolio, OviTex IHR is a reinforced biologic that uses layers of ovine (sheep) rumen interwoven with a polymer suture for added strength and is designed to minimize permanent polymer footprint.
“OviTex IHR, designed specifically for inguinal hernia repair and robotic-compatibility usage, is the next logical addition to our growing OviTex portfolio,” Tela Bio. President and CEO, Antony Koblish told the press. “The inguinal hernia market has historically been dominated by permanent synthetic mesh with few viable alternatives to address the shortcomings of those materials. With the introduction of OviTex IHR, we are addressing this need and providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response.”
OviTex has over 8 years of clinical experience with more than 45,000 implantations and 35 published or presented works demonstrating its clinical efficacy in hernia repair, based on sales and internal data. A prior retrospective study, Minimizing Retained Foreign Body in Hernia Repair Using a Novel Technique: Reinforced Biologic Augmented Repair (ReBAR), examined OviTex Core Permanent in a variety of hernia repair techniques and indications.
The study was led by Dr. Paul Szotek, Medical Director of the Indiana Hernia Center and included the analysis of 259 patients who underwent robotic inguinal hernia TAPP repair using the ReBAR technique. The study demonstrated a low 1.2% recurrence rate with an average follow-up of 1.5 years.
Available in three configurations, OviTex consists of a three or four-layer anatomically shaped device or a three-layer rectangular device. This provides surgeons with a variety of options to address unique patient, technique, or procedure-related characteristics. Each configuration is designed for trocar compatibility to enhance the use of these products in laparoscopic and robotic procedures.
Building on the existing OviTex portfolio, OviTex IHR is a reinforced biologic that uses layers of ovine (sheep) rumen interwoven with a polymer suture for added strength and is designed to minimize permanent polymer footprint.
“OviTex IHR, designed specifically for inguinal hernia repair and robotic-compatibility usage, is the next logical addition to our growing OviTex portfolio,” Tela Bio. President and CEO, Antony Koblish told the press. “The inguinal hernia market has historically been dominated by permanent synthetic mesh with few viable alternatives to address the shortcomings of those materials. With the introduction of OviTex IHR, we are addressing this need and providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient’s natural healing response.”
OviTex has over 8 years of clinical experience with more than 45,000 implantations and 35 published or presented works demonstrating its clinical efficacy in hernia repair, based on sales and internal data. A prior retrospective study, Minimizing Retained Foreign Body in Hernia Repair Using a Novel Technique: Reinforced Biologic Augmented Repair (ReBAR), examined OviTex Core Permanent in a variety of hernia repair techniques and indications.
The study was led by Dr. Paul Szotek, Medical Director of the Indiana Hernia Center and included the analysis of 259 patients who underwent robotic inguinal hernia TAPP repair using the ReBAR technique. The study demonstrated a low 1.2% recurrence rate with an average follow-up of 1.5 years.